Skip to content

A New Neuroregulatory Technology for the Therapy of AN Based on the Pathological Neural Network of ACC

A New Neuroregulatory Technology for the Therapy of AN Based on the Pathological Neural Network of ACC: A Multicenter Randomized Controlled Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06152640
Enrollment
80
Registered
2023-12-01
Start date
2024-04-30
Completion date
2026-05-31
Last updated
2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Feeding and Eating Disorders

Keywords

anorexia nervosa, Deep transcranial magnetic stimulation, anterior cingulate cortex

Brief summary

Hypothesis of AN-ACC pathological network suggests that ACC overactivation and abnormal functional connectivity with other brain regions is the neuropathological mechanism for the onset of AN. Currently, rare studies have been conducted on dTMS targeting ACC as an intervention in patients with AN. In this research, dTMS, a neuroregulatory technology, is used for the first time to intervene with ACC in the treatment of adult AN. A randomized controlled study design is adopted, in which patients with AN are divided into the dTMS treatment group and the pseudo-stimulation group by 1:1 randomization, followed by 6-week intervention and half-year follow up, to clarify the near-term and long-term efficacy and safety of the dTMS treatment. Meanwhile, baseline fMRI data will be extracted and combined with clinical features to establish an efficacy prediction model, which will provide theoretical and practical basis for the pioneering ACC-targeted dTMS treatment in China, helping to establish a new type of intervention program for AN, with expected results of innovation.

Detailed description

Building on the previous foundation and literature review, we found that ACC is closely related to the core symptoms of AN, and proposed the hypothesis of AN-ACC pathological network, suggesting that ACC overactivation and abnormal functional connectivity with other brain regions (anterior frontal lobe, parietal lobe, precuneus, and striatum) is the neuropathological mechanism for the onset of AN. Currently, rare studies have been conducted on dTMS targeting ACC as an intervention in patients with AN. In this research, dTMS, a neuroregulatory technology, is used for the first time to intervene with ACC in the treatment of adult AN. A randomized controlled study design is adopted, in which patients with AN are divided into the dTMS treatment group and the pseudo-stimulation group by 1:1 randomization, followed by a 28-day intervention (once a day) and half-year follow up, to clarify the near-term and long-term efficacy and safety of the dTMS treatment. Patients in both groups undergo fMRI examinations, complete delay discounting task (DDT) and body image task before and after each treatment session. Efficacy is judged by a weight gain of 4 kg in the four weeks following the intervention. Symptoms, psychometrics and side effect questionnaires are followed up at baseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 ( after completion of treatment). Meanwhile, baseline fMRI data will be extracted and combined with clinical features to establish an efficacy prediction model. We will explore factors predictive of dTMS efficacy in AN patients of dTMS treatment group, divided into two groups according to whether dTMS is effective or not after treatment (defined as a weight gain of 4 kg in the four weeks following the intervention), using pre-treatment (baseline) demographic information, psychological assessment questionnaires, and neuroimaging data in the two groups. This will provide theoretical and practical basis for the pioneering ACC-targeted dTMS treatment in China, helping to establish a new type of intervention program for AN, with expected results of innovation.

Interventions

Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling is used to obtain a greater depth of stimulation, up to about 6 cm below the cortex. dTMS intervention: The intervention targets are at the left and right ACC, once per day, for 28 days. A total of 28 treatments are given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses.

Neuronavigation: The sham coil is positioned 4 cm in front of the scalp point and foot motor cortex, corresponding to the ACC. Sham dTMS intervention: The intervention targets are at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), once per day, for 28 days. A total of 28 treatments are given.

OTHERBasic treatment

According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.

Sponsors

Shanghai Tongji Hospital, Tongji University School of Medicine
CollaboratorOTHER
Huadong Hospital
CollaboratorOTHER
Shanghai University of Traditional Chinese Medicine
CollaboratorOTHER
Shanghai Mental Health Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Female, aged 18-35 years, right handedness. * Above primary education. * Meet the diagnostic criteria of AN in DSM-V, and13.0 kg/m2 ≤ body mass index (BMI)\<18.5 kg/m2. * No systemic nutritional therapy, psychiatric medication or any form of psychotherapy have been received within 1 month before enrollment. * Able to understand the nature of this study and sign an informed consent form.

Exclusion criteria

* Diagnosed with a DSM-5 disease other than anorexia nervosa, or at high risk of suicide, strong impulsive behavior as well as anti-social behavior. * With severe physical or cognitive impairment. * Not able to undergo MRI. * Considered unsuitable for enrollment in this clinical trial for other reasons.

Design outcomes

Primary

MeasureTime frameDescription
Body Mass Index (BMI).whin 4 weeks after completion of treatmentCalculation: BMI = weight (kg) divided by the square of height (m)

Secondary

MeasureTime frameDescription
2.Eating Disorder Inventory (EDI-II)baseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 ( after completion of treatment).It is a commonly used scale for assessing cognitive-behavioral symptoms of eating disorders and is used to assess the severity of eating disorders. The scale contains 91 items divided into 8 subscales and 3 temporary subscales, including the pursuit of thinness, bulimia, body dissatisfaction, feelings of ineffectiveness, perfectionism, mistrust of others, introspection, maturity fears, abstinence, impulsive regulation and social insecurity.
3.Beck Depression Inventory (BDI)baseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 ( after completion of treatment).The BDI consists of 21 items and assesses the patient's accompanying feelings of depression over the past 2 weeks.
4.Beck Anxiety Inventory (BAI)baseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 ( after completion of treatment).The BAI consists of 21 items and assesses the patient's accompanying feelings of anxiety over the past 1 week.
1.Eating Disorder Examination Questionnaire (EDE-Q6.0)baseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 ( after completion of treatment).Eating Disorder Examination Questionnaire can assess the core symptoms of eating disorders, including behavioral and psychological characteristics, and rate their frequency and intensity, which can assess the severity of the eating disorder. It consists of 4 subscales, including dietary restriction, eating concerns, body image concerns, and weight concerns.
6. Body Image Tasksbaseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 (after completion of treatment).Tasks that address excessive concerns about body shape/weight include the following two parts: Body size estimation: The screen will present the above 30 body size pictures sequentially, the subjects will view the body size pictures in 4000ms, and then evaluate the body size of the body pictures in 4000ms, with a score of 1 representing very low body weight, 4 representing very overweight, and 4 representing very overweight. A score of 1 represents very low weight and a score of 4 represents very overweight. Body compare task: The screen will present the above 30 body images in turn, the subjects will have 4000ms to view their own images (with randomized distortions), and then they will have 4000ms to compare their actual body shape with the body shape in the images and assess their emotional level. 1 point represents very calm and 4 for very anxious.
7. Delay Discounting Task (DDT task)baseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 (after completion of treatment).The study uses a DDT task in a food choice scenario to assess inhibitory impulses. The task requires subjects to make a decision between choosing a small reward in the present or a large reward in the future. Inhibition to choose a small reward in the present implies a strong intertemporal decision-making ability. The task begins with an assessment of their hunger, willingness to eat, and emotional feelings at the moment. Then they are asked to rate 40 pictures of food on a scale of 0 to 10 on five dimensions: familiarity, craving, positive and negative emotions, emotional intensity, and eating control. Pictures of foods with craving scores \>7 and eating control \<5, as well as matched in familiarity and emotion for use in the ensuing delay discounting task. The choice is made by pressing a button: Patients choosing to get less food immediately are given fewer coupons after the delay. But those waiting for a period of time to get more food are given more coupons after the delay.
5. Self-assessed Compulsive Questionnaire for Eating Disorders (SR-YBC-EDS)baseline, day 28 (at the end of treatment), and weeks 4, 8, 12 and 24 ( after completion of treatment).The SR-YBC-EDS was developed based on the Yale-Brown Compulsive Questionnaire for Eating Disorders (YBC-EDS), consisting of two parts: the first part is a list of 65 symptomatic items, which is used to identify the subjects' obsessive-compulsive symptoms, and the second part is a list of 8 core items, which is used to assess the frequency and severity of obsessive-compulsive symptoms. All parts contain two dimensions: preoccupation and ritual behavior.

Countries

China

Contacts

Primary ContactJue Chen, PHD
chenjue2088@163.com+8618017311203

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026